Compare BDSX & USBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BDSX | USBC |
|---|---|---|
| Founded | 2005 | 1998 |
| Country | United States | United States |
| Employees | N/A | 31 |
| Industry | Precision Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.0M | 132.0M |
| IPO Year | 2020 | N/A |
| Metric | BDSX | USBC |
|---|---|---|
| Price | $13.29 | $0.34 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $32.50 | N/A |
| AVG Volume (30 Days) | 55.4K | ★ 424.3K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $88,499,000.00 | N/A |
| Revenue This Year | $25.26 | N/A |
| Revenue Next Year | $19.15 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 24.08 | N/A |
| 52 Week Low | $0.25 | $0.31 |
| 52 Week High | $20.21 | $1.97 |
| Indicator | BDSX | USBC |
|---|---|---|
| Relative Strength Index (RSI) | 43.74 | 44.37 |
| Support Level | $6.00 | $0.31 |
| Resistance Level | $16.26 | $0.42 |
| Average True Range (ATR) | 1.04 | 0.03 |
| MACD | -0.22 | 0.00 |
| Stochastic Oscillator | 26.76 | 18.35 |
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
USBC Inc is a multi-disciplinary technology company that is an innovator in digital financial technologies. The company develops financial services including digital assets and banking solutions, as well as non-invasive health monitoring research. USBC has implemented a Bitcoin treasury strategy to support development and research across its various divisions. A key focus is the further development of its tokenized deposit program, a tokenized representation of a U.S.-dollar-denominated bank deposit account that operates on blockchain technology and is embedded with digital identity, alongside its legacy non-invasive sensor technology business, with the objective of creating long-term shareholder value in an evolving financial landscape.